Gene · 2160
Papers2,705
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,705
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Intervention Effect and Mechanism of Regulating MiR-155 on Young Rats with Dysfunction of Blood Coagulation]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2024 | 38926979 | PubTator, text mining | PubMed |
| Minimal interference of concizumab with standard clinical coagulation laboratory assays - An in vitro study. | Haemophilia | 2024 | 38924198 | PubTator, text mining | PubMed |
| Every minute counts: A comparison of thawing times and haemostatic quality of plasma thawed at 37°C and 45°C using four different methods. | Transfus Med | 2024 | 38923078 | PubTator, text mining | PubMed |
| Altered fibrin clot phenotype in young adults with intracerebral hemorrhage of unknown cause: A case-control study. | Thromb Res | 2024 | 38901058 | PubTator, text mining | PubMed |
| The spectrum of factor XI deficiency in Southeast China: four recurrent variants can explain most of the deficiencies. | Orphanet J Rare Dis | 2024 | 38835089 | PubTator, text mining | PubMed |
| Coagulation factor XI in cirrhosis does not predict thrombo-hemorrhagic complications and hepatic decompensation. | Dig Liver Dis | 2024 | 38834381 | PubTator, text mining | PubMed |
| Identification of pleiotropic and specific therapeutic targets for cardio-cerebral diseases: A large-scale proteome-wide mendelian randomization and colocalization study. | PLoS One | 2024 | 38820305 | PubTator, text mining | PubMed |
| Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings. | Haematologica | 2024 | 38779744 | PubTator, text mining | PubMed |
| Gene-Gene Interaction Between Factor-XI and ABO Genes in Cerebral Venous Thrombosis: The BEAST Study. | Neurology | 2024 | 38759137 | PubTator, text mining | PubMed |
| Factor XI Inhibitors: perspectives in primary and secondary prevention of ischemic stroke. | Intern Emerg Med | 2024 | 38743127 | PubTator, text mining | PubMed |
| Factor XI antagonists: the discovery of the philosopher's stone? | Clin Kidney J | 2024 | 38742210 | PubTator, text mining | PubMed |
| [Molecular mechanism analysis of a family with hereditary coagulation F Ⅺ deficiency caused by compound heterozygous mutations]. | Zhonghua Xue Ye Xue Za Zhi | 2024 | 38716603 | PubTator, text mining | PubMed |
| Removal of endothelial surface-associated von villebrand factor suppresses accelerate datherosclerosis after myocardial infarction. | J Transl Med | 2024 | 38693516 | PubTator, text mining | PubMed |
| [New anticoagulants in 2024: Development of factor XI and XIa inhibitors]. | Ann Biol Clin (Paris) | 2024 | 38638015 | PubTator, text mining | PubMed |
| Clinical value of coagulation parameters in predicting the severity of severe fever with thrombocytopenia syndrome. | Front Microbiol | 2024 | 38633697 | PubTator, text mining | PubMed |
| Factor XI: structure, function and therapeutic inhibition. | J Thromb Thrombolysis | 2024 | 38622277 | PubTator, text mining | PubMed |
| Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. | Clin Transl Sci | 2024 | 38563414 | PubTator, text mining | PubMed |
| Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose-escalation phase I study. | Clin Transl Sci | 2024 | 38558535 | PubTator, text mining | PubMed |
| Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition. | Curr Res Pharmacol Drug Discov | 2024 | 38545505 | PubTator, text mining | PubMed |
| A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. | Kidney Int | 2024 | 38537676 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2160/papers?page=12